

Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis

PENG CHEN^{1*}, LONG WANG^{2*}, HAO LI³, BING LIU⁴ and ZUI ZOU⁵

¹Department of Stomatology, Chinese People's Liberation Army General Hospital, Haidian, Beijing 100853;

²Department of Anesthesiology, The Eastern Hepatobiliary Hospital, Shanghai 200438;

³Department of Anesthesiology, Chinese People's Liberation Army General Hospital, Haidian, Beijing 100853;

⁴Department of Stomatology, The General Hospital of the Air Force of the Chinese People's Liberation Army, Beijing 100142;

⁵Department of Anesthesiology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China

Received December 9, 2012; Accepted March 11, 2013

DOI: 10.3892/ol.2013.1301

Abstract. Hypomagnesemia is a serious adverse event for patients treated with cetuximab, an inhibitor of endothelial growth factor receptor (EGFR). However, no significant association has yet been established between cetuximab and hypomagnesemia in randomized controlled clinical trials (RCTs). The present study conducted a systematic review and meta-analysis of published RCTs to assess the overall risk of hypomagnesemia associated with cetuximab. PubMed, the Cochrane Central Register of Controlled Trials, Embase and the American Society of Clinical Oncology conferences were searched for relevant RCTs. Quantitative analysis was carried out to evaluate the association between hypomagnesemia and cetuximab. A total of 7,045 patients with a variety of advanced cancers from 10 trials were included in the analysis. The overall incidence of grade 3/4 hypomagnesemia in patients receiving cetuximab was 3.9% [95% confidence interval (CI), 2.6-4.3%]. Patients treated with cetuximab had a significantly increased risk of grade 3/4 hypomagnesemia compared with patients treated with control medication, with a relative risk (RR) of 8.60 (95% CI, 5.08-14.54). Risk was observed to vary with tumor type. The study concluded that cetuximab is associated with a significant risk of hypomagnesemia in patients with advanced cancer receiving concurrent chemotherapy.

Introduction

The endothelial growth factor receptor (EGFR), which is present in numerous cell types, is a transmembrane protein consisting of an extracellular binding domain, a hydrophobic transmembrane segment and a cytoplasmic tyrosine kinase domain, and is considered one of the best characterized ligand-receptor systems (1). Overexpression of EGFR has been identified in a variety of solid tumors (2), and EGF has played a crucial role in disease progression, poor prognosis and reduced sensitivity to chemotherapy (3). Therefore, blocking the signaling of EGF has been a major focus of new cancer therapies.

Cetuximab is a human-murine monoclonal antibody directed against the EGFR protein, which is expressed on the surface of human tumor cells (4). Cetuximab was approved by the Food and Drug Administration (FDA) for use against metastatic colorectal cancer in February 2004 (5) and first gained approval in Europe for use in the treatment of EGFR-expressing metastatic colorectal cancer following the failure of irinotecan-containing regimens (6). More recently, a meta-analysis demonstrated an improved overall survival (OS) in non-small cell lung cancer patients receiving chemotherapy plus cetuximab compared with chemotherapy alone (7). The clinical efficacy of cetuximab in a number of other malignancies, including head and neck cancer and pancreatic cancer, is currently undergoing extensive evaluation.

With the use of cetuximab, substantial adverse events have been observed. Rashes, diarrhea, fatigue, neutropenia, hypertension, nausea, infusion-related or hypersensitivity reactions, and hand-foot skin reactions were extremely common when cetuximab was first administered for advanced cancer. In September 2005, the FDA released a warning about the possibility of severe hypomagnesemia in relation to cetuximab therapy (8). A large number of patients with metastatic colorectal cancer receiving cetuximab developed severe hypomagnesemia that was refractory to oral magnesium supplementation (9,10). However, no significant association has yet been established between cetuximab and hypomagnesemia in randomized controlled clinical trials (RCTs). Thus,

Correspondence to: Dr Zui Zou, Department of Anesthesiology, Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Shanghai 200003, P.R. China
E-mail: zouzui1980@yahoo.com.cn

Dr Bing Liu, Department of Stomatology, The General Hospital of the Air Force of the Chinese People's Liberation Army, No. 30 Fucheng Road, Haidian, Beijing 100142, P.R. China
E-mail: liubingcp@yahoo.com.cn

*Contributed equally

Key words: cetuximab, hypomagnesemia, advanced cancer, meta-analysis

we undertook a systematic review of the relevant RCTs to evaluate the risk of hypomagnesemia associated with cetuximab treatment for advanced cancer.

Materials and methods

Data source. An extensive search of PubMed (up to March, 2012), the Cochrane Central Register of Controlled Trials (up to Cochrane Library Issue 3, 2012), and Embase (up to March, 2012) was conducted to identify relevant RCTs for the meta-analysis, using the keywords; 'cetuximab', 'erbitux', 'cancer' and 'hypomagnesemia'. Abstracts and virtual meeting presentations from the American Society of Clinical Oncology conferences held between January 2000 and March 2012 were also searched for relevant RCTs. The reference lists of articles, reviews, letters to the editor and case reports were also searched to find those not yet included in the computerized databases. The language of the research papers was not restricted.

Study selection. RCTs that directly compared advanced cancer patients treated with and without cetuximab, respectively, were selected for the analysis. Phase I and single-arm phase II trials were excluded due to the lack of control groups. Specifically, clinical trials that met the following criteria were included in the meta-analysis: i) prospective phase II and phase III RCTs in patients with advanced cancer; ii) random assignment of participants to cetuximab treatment or control group (placebo or best supportive care), in addition to concurrent chemotherapy and/or treatment with a biological agent; and iii) available data, including events or incidences of hypomagnesemia and sample size for analysis.

Data extraction. Two researchers independently extracted data from each identified trial using a predesigned review form. The following data were included: authors of each study, publication year, trial design, number of patients, number of patients eligible for hypomagnesemia evaluation, age, gender, intervention, dose of cetuximab administered, cancer type, phase of trial, follow-up time, allocation concealment, blinded analysis and events or incidences of hypomagnesemia.

Qualitative assessment. The studies were appraised independently by two authors based on the standard criteria (randomization, blinding, loss to follow-up and generation of allocation concealment), and additional quantitative quality was assessed using the scoring system developed by Jadad *et al* (11), appropriately modified according to the treatments under study. The quality scoring system was as follows: i) adequacy of randomization, coded as properly used with detailed description of randomization (score 2), randomized but details not reported (score 1) and inappropriate randomization (score 0); ii) allocation concealment, coded as properly used (score 2), unclear (score 1) and not used (score 0); iii) blinded method, coded as double blind (score 2), single-blind (score 1) and open label or unclear (score 0); iv) drop-outs and follow-ups, coded as data given (score 1), and data not given (score 0). Any disagreement was resolved by discussion.




Figure 1. Selection process for RCTs included in the meta-analysis. RCTs, randomized controlled clinical trials.

Clinical end-points. The primary end-point was the incidence of hypomagnesemia. Hypomagnesemia in these studies was assessed and recorded according to the Common Terminology Criteria for Adverse Events (version 2 or 3) (12,13).

Statistical analysis. Stata version 10.0 software (StataCorp., College Station, TX, USA) was used for the statistical analysis. The incidence of hypomagnesemia was calculated using the number of patients with hypomagnesemia in the cetuximab group and the total number of patients receiving cetuximab treatment. The proportion of patients with hypomagnesemia was calculated and the 95% confidence interval (CI) was derived for each trial.

The Chi-square test of heterogeneity and the I^2 measure of inconsistency were used to assess the heterogeneity between trials. With an I^2 value of >50% indicating significant heterogeneity, the following techniques were used as explanations: (a) subgroup analysis; (b) sensitivity analysis performed by excluding the trials which potentially biased the results; and (c) the random effects model was used to explore the cause of the heterogeneity. The Begg's test was used to determine the presence of publication bias with regard to the primary variable [relative risk (RR) of hypomagnesemia]. A two-tailed P-value of <0.05 was considered to indicate a statistically significant difference.

Results

Identification of included studies. A total of 155 clinical studies relevant to cetuximab were identified by the literature search. Review articles, case reports, meta-analyses, observational studies (n=48), phase I studies (n=14), single-arm phase II studies (n=20), duplicates (n=20), studies in which the control and treatment groups each received cetuximab (n=28) and those data not adequate for assessment of severe neutropenia (n=15; Fig. 1) were excluded. Ultimately, 10 RCTs, including five phase II and five phase III studies, were selected for analysis, involving a total of 7,045 patients. The main characteristics

Table I. Characteristics of randomized controlled clinical trials (RCTs) included in the meta-analysis.

First author (ref.)	Trial phase	Number of patients enrolled	Number for analysis	Underlying malignancy	Concurrent treatment	Jaded score	Cetuximab dose (mg/m ² per week)
Tol (21)	III	389	389	Colorectal cancer	Capecitabine, oxaliplatin and bevacizumab	3	250
Lynch (15)	III	676	645	Non-small cell lung cancer	Paclitaxel or docetaxel	3	250
Jonker (19)	III	572	566	Colorectal cancer	Fluoropyrimidine, irinotecan and oxaliplatin		250
Alberts (22)	III	2686	1825	Colorectal cancer	Fluorouracil, leucovorin and irinotecan	4	250
Maughan (23)	III	1634	1634	Colorectal cancer	Oxaliplatin and fluoropyrimidine	3	250
Adams (16)	III	804	804	Colorectal cancer	Leucovorin, oxaliplatin and ilorouracil or oxaliplatin and capecitabine		250
Vermorken (20)	III	442	434	Head and neck cancer	Fluorouracil, cisplatin or carboplatin	4	250
Sobrero (17)	III	1298	1267	Colorectal cancer	Irinotecan	3	250
Butts (18)	II	131	130	Non-small cell lung cancer	Cisplatin or carboplatin	3	250
Burtness (14)	III	117	116	Head and neck cancer	Cisplatin and placebo	5	125

(type of study design, underlying malignancy of included patients, concurrent treatment and number of patients) of the 10 included RCTs are presented in Table I. Randomized treatment allocation sequences were generated in all trials. Only one trial was double-blinded and placebo-controlled (14), five of the trials were open-label (15-19) and four trials were not specified (20-23). All trials reported the number and reason of withdrawals and drop-outs. None mentioned allocation concealment. A total of seven trials were described as multi-center trials and three did not mention their status (19,20,23). The median follow-up time for four of the studies (18,19,21,22) ranged from 6.8 to 31 months, while six studies did not state this factor. Hypomagnesemia was assessed and recorded according to the National Cancer Institute's Common Toxicity Criteria, version 2 or 3 (12,13). The baseline Eastern Cooperative Oncology Group (ECOG) performance status of all patients was between 0 and 2. Patients were required to have adequate hepatic, renal and hematological function. The underlying malignancies observed consisted of colorectal cancer (six studies), non-small cell lung cancer (two studies) and head and neck cancer (two studies).

Risk of hypomagnesemia for cetuximab administration. As no heterogeneity was found among the included studies in the overall analysis (all-grades of hypomagnesemia I^2 , 60.7%, $P=0.037$; grade 3/4 I^2 , 9.6%, $P=0.354$), the fixed-effects model was used. The overall RR of grade 3/4 hypomagnesemia with cetuximab versus control was 8.60 (95% CI, 5.08-14.54; Fig. 2), indicating a significantly higher incidence of grade 3/4 hypomagnesemia in the cetuximab groups. The RR of the subgroup analysis suggested a significant association between grade 3/4 hypomagnesemia and cetuximab treatment among patients with non-small cell lung cancer (RR, 9.28; 95% CI, 2.83-30.39; Fig. 2). The RR of grade 3/4 hypomagnesemia was lowest in patients with head and neck cancer treated with cetuximab compared with controls (RR, 6.18; 95% CI, 2.19-17.49), and highest in patients with colorectal cancer (RR, 9.50; 95% CI, 4.67-19.34). Of all the trials, five reported that the cetuximab groups had a higher incidence of grade 3/4 hypomagnesemia compared with the control groups.

Incidence of hypomagnesemia for cetuximab administration. The overall incidence of grade 3/4 hypomagnesemia in the patients receiving cetuximab was 3.9% (95% CI, 2.6-4.3). Patients with differing tumors may be at varying risks of grade 3/4 hypomagnesemia due to differences in tumor malignancy and the associated treatments. The present study explored whether having a specific type of cancer was associated with a higher risk of severe neutropenia compared with other cancers. As shown in Table II, the risk of grade 3/4 hypomagnesemia varied according to the tumor type. The highest incidence of grade 3/4 hypomagnesemia was observed in patients with non-small cell lung cancer (9.0%; 95% CI, 5.0-15.4), while the lowest incidence was observed in patients with colorectal cancer (2.9%; 95% CI, 1.7-3.1).


Publication bias. No publication bias was detected for the primary variable of the present study (RR of grade 3/4 hypomagnesemia) by Begg's and Egger's tests ($P=0.38$; $P=0.29$, respectively).

Table II. Incidence of grade 3/4 hypomagnesemia with cetuximab among patients with various tumor types.

Tumor type	Number of studies	Cetuximab	Control	Incidence (95% CI)
Overall	10	135 (3437)	16 (3608)	0.039 (0.026-0.043)
Colorectal cancer	6	82 (2769)	9 (2947)	0.029 (0.017-0.031)
Non-small cell lung cancer	2	25 (279)	4 (275)	0.090 (0.050-0.154)
Head and neck cancer	2	28 (389)	3 (386)	0.07 (0.015-0.177)

Data are presented as number of patients with grade 3/4 hypomagnesemia (number included in the present study). CI, confidence interval.

ALL GRADE



GRADE 3/4




Figure 2. Relative risk (RR) of hypomagnesemia associated with cetuximab treatment compared with control treatment. RR<1, numerically lower incidence than control chemotherapy; RR>1, numerically higher incidence than control chemotherapy. If 95% CI does not include the number 1 it demonstrates a significant difference between the two groups (P<0.05).

Discussion

Hypomagnesemia may result in cardiac arrhythmia, coronary artery vasospasm and sudden cardiac death. Adequate management of hypomagnesemia is important for the numerous patients who receive cetuximab-based therapy. However, the symptoms of hypomagnesemia may be fairly non-specific, including irritability, paresthesia and severe fatigue, which may easily be attributed to the underlying tumor or to previous chemotherapy regimens (24). Hypomagnesemia is often ignored in studies, and serum magnesium levels should be monitored better when cetuximab-based therapy is performed for advanced cancer. In RCTs discussing the association of hypomagnesemia and cetuximab, an individual RCT is not powerful enough to detect a significant correlation; therefore the contribution of cetuximab to the development of hypomagnesemia is difficult to assess. The present study combined 10 RCTs to overcome this limitation. The result demonstrated a high incidence of grade 3/4 hypomagnesemia (3.9%; 95% CI, 2.6-4.3) associated with cetuximab treatment for advanced cancer. Cetuximab treatment had a higher risk of grade 3/4 hypomagnesemia compared with the control (RR, 8.60; 95% CI, 5.08-14.54). The present study also showed that the risk of grade 3/4 hypomagnesemia with cetuximab may vary with the tumor type. Patients with advanced colorectal cancer had the highest incidence of grade 3/4 hypomagnesemia.

The mechanisms behind this toxicity have not been well defined. Numerous studies on hereditary renal Mg^{2+} -wasting syndromes and inborn errors of the Mg^{2+} balance demonstrated that several new proteins were involved in transepithelial Mg^{2+} transport in the distal convoluted tubule, including the Mg^{2+} -permeable channel TRPM6 (transient receptor potential cation channel, subfamily M, member 6) and TRPM7 (25-27). Groenestegge *et al* (28) revealed that *in vitro* cetuximab preincubation abolished the stimulatory effect of EGF on TRPM6 activity. Moreover, EGFR is highly expressed in the kidney, particularly in the ascending limb of the loop of Henle, where 70% of filtered Mg^{2+} is reabsorbed. Cetuximab, as an EGFR blockade, may affect Mg^{2+} transport (29). However, this effect has not been described with other small molecule anti-EGFR agents, such as gefitinib and erlotinib. Thus, a pure anti-EGFR effect does not adequately explain this toxicity. Recent data from panitumumab clinical trials have also reported hypomagnesemia toxicity in patients with metastatic colorectal cancer (30). This suggests that hypomagnesemia toxicity is a monoclonal antibody anti-EGFR-specific phenomenon.

There are several limitations in the present study analysis that require consideration. Firstly, the meta-analysis results are affected by clinical heterogeneity. The trials have varying patient clinical profiles, concurrent chemotherapies, lengths of follow-up and lengths of treatment; thus, differences among trials are inevitable, and there is always some heterogeneity, even within individual trials. However, heterogeneity does not necessarily preclude pooling of the results since individual patients are only directly compared with other patients within the same trial and not across trials (31,32). Given the uncertainty resulting from this clinical heterogeneity, subgroup analyses were performed in the present meta-analysis. Secondly, the meta-analysis only included 10 studies out of

155 identified in the literature search. In this regard, only those trials conducted with a rigorous methodology were selected in order to provide solid conclusions. Meta-analyses often include small numbers of studies and heterogeneity is therefore a necessary consequence. Higgins *et al* evaluated Cochrane reviews and identified that 67% included five studies and that 20% included ten studies (33). A lower threshold for the number of studies to be included in a meta-analysis has not yet been established. Finally, not all articles had data available on all grades of hypomagnesemia.

In conclusion, the present study showed that cetuximab is associated with a significant risk of hypomagnesemia in patients with advanced cancer who were receiving concurrent chemotherapy. This risk varies with the tumor type. Early monitoring of hypomagnesemia is important when cetuximab-based therapy is performed. Patients undergoing cetuximab administration with grade 3/4 of hypomagnesemia should receive appropriate and aggressive replacement therapy due to the high risk of cardiac arrhythmias and sudden mortality.

References

1. Milano G, Spano JP and Leyland-Jones B: EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality. *Br J Cancer* 99: 1-5, 2008.
2. Heist RS and Christiani D: EGFR-targeted therapies in lung cancer: predictors of response and toxicity. *Pharmacogenomics* 10: 59-68, 2009.
3. Brandes AA, Franceschi E, Tosoni A, Hegi ME and Stupp R: Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. *Clin Cancer Res* 14: 957-960, 2008.
4. Reynolds NA and Wagstaff AJ: Cetuximab: in the treatment of metastatic colorectal cancer. *Drugs* 64: 109-121, 2004.
5. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 351: 337-345, 2004.
6. Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenzl M, Mrcic-Krmpotic Z, Shacham-Shmueli E, Vrbanc D, Esser R, Scheithauer W and Zielinski CC: Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. *World J Gastroenterol* 16: 3133-3143, 2010.
7. Chen P, Wang L, Liu B, Zhang HZ, Liu HC and Zou Z: EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis. *Eur J Clin Pharmacol* 67: 235-243, 2011.
8. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, Freyer G, Philip T and Biron P: Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. *J Clin Oncol* 14: 636-643, 1996.
9. Crawford J, Dale DC and Lyman GH: Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. *Cancer* 100: 228-237, 2004.
10. Fakih MG, Wilding G and Lombardo J: Cetuximab-induced hypomagnesemia in patients with colorectal cancer. *Clin Colorectal Cancer* 6: 152-156, 2006.
11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ and McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 17: 1-12, 1996.
12. Okayama N, Nishioka M, Hazama S, Sakai K, Suehiro Y, Maekawa M, Sakamoto J, Iwamoto S, Kato T, Mishima H, Oka M and Hinoda Y: The importance of evaluation of DNA amplifiability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues. *Jpn J Clin Oncol* 41: 165-171, 2011.
13. Wu L, Parton A, Lu L, Adams M, Schafer P and Bartlett JB: Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. *Cancer Immunol Immunother* 60: 61-73, 2011.

14. Burtneß B, Goldwasser MA, Flood W, Mattar B and Forastiere AA: Eastern Cooperative Oncology Group: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. *J Clin Oncol* 23: 8646-8654, 2005.
15. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, Pautret V, Weber MR and Woytowitz D: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. *J Clin Oncol* 28: 911-917, 2010.
16. Adams RA, Meade AM, Madi A, Fisher D, Kay E, Kenny S, Kaplan RS and Maughan TS: Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. *Br J Cancer* 100: 251-258, 2009.
17. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J and Burris HA III: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. *J Clin Oncol* 26: 2311-2319, 2008.
18. Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y, Kreisman H, Graze P, Maher J, Ross HJ, Ellis PM, McNulty W, Kaplan E, Pautret V, Weber MR and Shepherd FA: Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. *J Clin Oncol* 25: 5777-5784, 2007.
19. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C and Moore MJ: Cetuximab for the treatment of colorectal cancer. *N Engl J Med* 357: 2040-2048, 2007.
20. Vermorken JB, Mesia R, Rivera F, Remenar E, Kaweckí A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N and Hitt R: Platinum-based chemotherapy plus cetuximab in head and neck cancer. *N Engl J Med* 359: 1116-1127, 2008.
21. Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, Mol L, Antonini NF and Punt CJ: A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. *Ann Oncol* 19: 734-738, 2008.
22. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH Jr, Pockaj BA, Grothey A and Goldberg RM: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. *JAMA* 307: 1383-1393, 2012.
23. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R and Cheadle JP; MRC COIN Trial Investigators: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. *Lancet* 377: 2103-2114, 2011.
24. Schrag D, Chung KY, Flombaum C and Saltz L: Cetuximab therapy and symptomatic hypomagnesemia. *J Natl Cancer Inst* 97: 1221-1224, 2005.
25. Touyz RM: Transient receptor potential melastatin 6 and 7 channels, magnesium transport, and vascular biology: implications in hypertension. *Am J Physiol Heart Circ Physiol* 294: H1103-H1118, 2008.
26. Walder RY, Landau D, Meyer P, Shalev H, Tsolia M, Borochowitz Z, Boettger MB, Beck GE, Englehardt RK, Carmi R and Sheffield VC: Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. *Nat Genet* 31: 171-174, 2002.
27. Schlingmann KP, Weber S, Peters M, Niemann Nejsum L, Vitzthum H, Klingel K, Kratz M, Haddad E, Ristoff E, Dinour D, Syrrou M, Nielsen S, Sassen M, Waldegger S, Seyberth HW and Konrad M: Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. *Nat Genet* 31: 166-170, 2002.
28. Groenestege WM, Thébault S, van der Wijst J, van den Berg D, Janssen R, Tejpar S, van den Heuvel LP, van Cutsem E, Hoenderop JG, Knoers NV and Bindels RJ: Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. *J Clin Invest* 117: 2260-2267, 2007.
29. Vincenzi B, Santini D and Tonini G: Biological interaction between anti-epidermal growth factor receptor agent cetuximab and magnesium. *Expert Opin Pharmacother* 9: 1267-1269, 2008.
30. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M and Barni S: Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. *Expert Opin Drug Saf* 11 (Suppl 1): S9-S19, 2012.
31. Lau J, Ioannidis JP and Schmid CH: Summing up evidence: one answer is not always enough. *Lancet* 351: 123-127, 1998.
32. Thompson SG: Why sources of heterogeneity in meta-analysis should be investigated. *BMJ* 309: 1351-1355, 1994.
33. Higgins J, Thompson S, Deeks J and Altman D: Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. *J Health Serv Res Policy* 7: 51-61, 2002.